Cipla Limited will host an earnings conference call on October 27, 2026, to discuss its Q2FY27 financial performance. The company will also release its unaudited financial results for the quarter on the same date.

The conference call is scheduled for 4:00 pm IST. Leadership team members will present the financial data and address questions from analysts and investors. A transcript of the session will be made available on the company's official website following the event.

Conference Call Details

Participants can join the call via universal access numbers or toll-free lines available in the USA, UK, Hong Kong, and Singapore. Registration links are provided for specific dial-in access.

Regulatory Filing

This announcement was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was signed by Rajendra Chopra, Company Secretary, on October 13, 2026.

Cipla 's unit has had its drug sale licence cancelled by the Maharashtra Food and Drug Administration (FDA) over alleged violations, according to a newspaper report.

Regulatory action against Cipla unit

The Maharashtra FDA took the step of cancelling the drug sale licence of the Cipla unit, citing alleged violations. The development was reported by a newspaper, and no further operational or financial details were provided in the source report.

Context

The cancellation of a drug sale licence by a state-level drug regulator represents a significant regulatory action for any pharmaceutical entity. The Maharashtra FDA is the authority responsible for overseeing drug manufacturing, sale, and distribution compliance within the state. No additional details regarding the nature of the alleged violations or the specific unit involved were available in the source data.